New Hope for Diabetes and Obesity Patients
US pharmaceutical giant Eli Lilly has launched its popular drug Mounjaro in India. The drug received approval from the Central Drugs Standard Control Organisation (CDSCO) and is now available in the country.
Mounjaro is used to manage type 2 diabetes and obesity. It works by activating two key hormones, GIP and GLP-1, to control blood sugar and appetite. The drug is taken once a week and should be used along with a healthy diet and regular exercise.
Who Can Use Mounjaro?
Doctors may prescribe Mounjaro for:
Adults with obesity (BMI of 30 or more)
Overweight adults (BMI of 27 or more) with health issues related to weight
Adults with type 2 diabetes for better blood sugar control
Strong Clinical Trial Results
Mounjaro has shown promising results in global studies:
Weight Loss (SURMOUNT-1 Study): Patients lost up to 21.8 kg over 72 weeks.
Diabetes Control (SURPASS Study): Patients saw a 2.4% drop in blood sugar levels over 40 weeks.
A Major Health Concern in India
India has 101 million people with diabetes. Nearly half of them struggle to control their blood sugar. Obesity is also rising, affecting around 100 million people in the country.
Eli Lilly India’s President, Winselow Tucker, said the company is committed to improving treatment options. “Our goal is to help people with obesity and diabetes live healthier lives,” he said.
With the launch of Mounjaro, Indian patients now have a new and effective treatment option.
